Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | AGXT | P21549 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.38 |
| ▸ | ATP4A | P20648 | 1/20 | 0.38 |
| ▸ | ATP4B | P51164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.36 |
| ▸ | BRS3 | P32247 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5197626 | 0.88 | KMT2A (0.41) | WDR5KMT2ARAB9ANPC1AGXT | |
| SCHEMBL4958916 | 0.88 | KMT2A (0.41) | WDR5KMT2ARAB9ANPC1AGXT | |
| SCHEMBL9812452 | 0.88 | KMT2A (0.41) | WDR5KMT2ARAB9ANPC1AGXT | |
| SCHEMBL13019030 | 0.87 | AGXT (0.38) | WDR5KMT2AAGXTPDE10ASHMT2 | |
| SCHEMBL13136704 | 0.87 | PKM (0.42) | WDR5KMT2ARAB9ANPC1AGXT | |
| SCHEMBL12021142 | 0.86 | BRS3 (0.46) | WDR5KMT2AAGXTPDE10ASHMT2 | |
| SCHEMBL21029237 | 0.86 | KMT2A (0.45) | WDR5KMT2ARAB9ANPC1AGXT | |
| SCHEMBL14344286 | 0.86 | KMT2A (0.45) | WDR5KMT2ARAB9ANPC1AGXT | |
| SCHEMBL2592828 | 0.86 | KMT2A (0.45) | WDR5KMT2ARAB9ANPC1AGXT | |
| SCHEMBL9446025 | 0.86 | KMT2A (0.40) | WDR5KMT2AAGXTPDE10ASHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298205-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS RELATED TO GASTRIC ACID SECRETION | SHEN JIE | 2010-11-25 | — | — | US | disclosed |
| US-20100298205-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS RELATED TO GASTRIC ACID SECRETION | SHEN JIE | 2010-11-25 | — | — | US | disclosed |
| US-20100222390-A1 | Methods and Compositions for the Intravenous Administration of Compounds Related to Proton Pump Inhibitors | ALEVIUM PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222390-A1 | Methods and Compositions for the Intravenous Administration of Compounds Related to Proton Pump Inhibitors | ALEVIUM PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| EP-1020460-B1 | The sodium salt of the (-)-enantiomer of omeprazole | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | EP | disclosed |
| US-20090048302-A1 | Methods and compositions for the treatment of conditions related to gastric acid secretion | ALLERGAN, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048302-A1 | Methods and compositions for the treatment of conditions related to gastric acid secretion | ALLERGAN, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20070161679-A1 | Method and compositions for the intravenous administration of compounds related to proton pump inhibitors | ALLERGAN, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161679-A1 | Method and compositions for the intravenous administration of compounds related to proton pump inhibitors | ALLERGAN, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070060621-A1 | Methods and compositions for the administration of prodrugs of proton pump inhibitors | HUGHES PATRICK M | 2007-03-15 | — | — | US | disclosed |
| US-20070060621-A1 | Methods and compositions for the administration of prodrugs of proton pump inhibitors | HUGHES PATRICK M | 2007-03-15 | — | — | US | disclosed |
| EP-0233284-B1 | PHARMACOLOGICAL COMPOUNDS | Aktiebolaget Hässle (SE) | 1992-08-19 | — | — | EP | disclosed |
| US-5021433-A | 2-(pryidylmethylthio) benzimidazole derivatives; antisecretory antiulcer agents | AKTIEBOLAGET HASSLE (SE) | 1991-06-04 | — | — | US | disclosed |
| EP-0221041-A2 | Benzimidazole derivatives, process for their preparation and their pharmaceutical use | Aktiebolaget Hässle (SE) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060621-A1 | Methods and compositions for the administration of prodrugs of proton pump inhibitors | SI, PPA1, PHPT1 | WDR5 4477/4885KMT2A 2927/4885RAB9A 876/4885 |
| US-20100298205-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS RELATED TO GASTRIC ACID SECRETION | ABCB11, SLC10A2, SLC47A2 | WDR5 4307/4885KMT2A 4404/4885RAB9A 1019/4885 |
| US-20100222390-A1 | Methods and Compositions for the Intravenous Administration of Compounds Related to Proton Pump Inhibitors | SI, ATP6V1G1, ATP6V1H | WDR5 4663/4885KMT2A 2885/4885RAB9A 670/4885 |
| US-20070161679-A1 | Method and compositions for the intravenous administration of compounds related to proton pump inhibitors | SI, ATP6V1G1, ATP6V1H | WDR5 4634/4885KMT2A 2966/4885RAB9A 690/4885 |
| US-20090048302-A1 | Methods and compositions for the treatment of conditions related to gastric acid secretion | ABCB11, SLC10A2, SLC47A2 | WDR5 4307/4885KMT2A 4404/4885RAB9A 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.